SCHEMBL6437786

SCHEMBL6437786

COC[C](C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27454119 0.75
SCHEMBL6434717 0.72
SCHEMBL1926176 0.72
SCHEMBL25403 0.72
SCHEMBL21962233 0.72
SCHEMBL11321316 0.70
Methoxyacetic Acid SCHEMBL28383111 0.69 FFAR3 (0.44)
Methoxyacetic Acid SCHEMBL585468 0.69 FFAR3 (0.44)
SCHEMBL27565265 0.69
SCHEMBL7022197 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4364921-A RADIOPACITY SCHERING, AKTIENGESELLSCHAFT (DE) 1982-12-21 US claimed
EP-2976340-B1 CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME (US) 2018-06-13 EP disclosed
CN-1984892-A Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions BRISTOL MYERS SQUIBB PHARMA CO (US) 2007-06-20 CN disclosed
EP-1172400-B1 THERMOPLASTIC RESIN FILM WITH SATISFACTORY PRINTABILITY YUPO CORP (JP) 2005-12-28 EP disclosed
US-6586106-B2 Ink transfer, adhesion and aging stability, and being satisfactory in back ghost when offset printing using oxidation polymerization type ink is performed on both faces YUPO CORPORATION (JP) 2003-07-01 US disclosed
US-20020054991-A1 Thermoplastic resin film satisfactory in printability YUPO CORPORATION (JP) 2002-05-09 US disclosed
EP-1172400-A1 THERMOPLASTIC RESIN FILM WITH SATISFACTORY PRINTABILITY Yupo Corporation (JP) 2002-01-16 EP disclosed
EP-0853626-A1 SUBSTITUTED PHOSPHINIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Novartis AG (CH) 1998-07-22 EP disclosed
WO-1997009335-A1 SUBSTITUTED PHOSPHINIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS NOVARTIS AG (CH) 1997-03-13 WO disclosed
EP-0463560-B1 New antiepileptic agents CIBA GEIGY AG (CH) 1995-10-25 EP disclosed
US-5424441-A Nootropic, antiepileptic agents CIBA-GEIGY CORPORATION (US) 1995-06-13 US disclosed
US-5407922-A GABA antagonists CIBA-GEIGY CORPORATION (US) 1995-04-18 US disclosed
US-5332729-A Nootropic, antiepileptic agents CIBA-GEIGY CORPORATION (US) 1994-07-26 US disclosed
EP-0569333-A2 Novel N-aralkyl and N-heteroaralkylamino alcane phosphinic acids CIBA-GEIGY AG (CH) 1993-11-10 EP disclosed
US-5229379-A Gamma-aminobutyric acid antagonists CIBA-GEIGY CORPORATION (US) 1993-07-20 US disclosed
EP-0463560-A1 New antiepileptic agents CIBA-GEIGY AG (CH) 1992-01-02 EP disclosed